Recent Concerns Around Thyroid Medications

In recent months, our practice has seen a growing number of patient and client concerns surrounding thyroid medications. Many individuals are experiencing challenges with accessibility, whether due to recalls, prescription limitations, or broader changes in the pharmaceutical regulatory environment. These issues have left many people feeling uncertain and frustrated, especially when consistent access to thyroid medication is such a vital part of their daily health management.

 

While there are several moving pieces within the current thyroid prescription landscape, our goal is to bring clarity and perspective. We’ll explore the most pressing concerns we are hearing, share our thoughts on the long-term role of thyroid medications, and, most importantly, discuss why root-cause healing remains essential. 

 

If you’ve been feeling the weight of these challenges or are wondering what they mean for your long-term health, you’re not alone. 

 

Let’s take a closer look at what’s happening and how to move forward with well-informed decisions. 

 

What Is Thyroid Hormone?

 

 

Thyroid hormone is one of the body’s most essential chemical messengers, produced by the thyroid gland—a small, butterfly-shaped gland located at the base of the neck. These hormones act as regulators of metabolism, controlling how efficiently cells convert oxygen and nutrients into usable energy. 

 

They influence virtually every system in the body, including heart rate, body temperature, digestion, muscle strength, and brain function. Because of this, even subtle changes in thyroid hormone levels can have wide-reaching effects on overall health and well-being.

 

From a clinical perspective, thyroid hormone is not a single substance but rather a group of related hormones that work together in a delicate balance. The thyroid gland primarily produces thyroxine (T4), which is considered a storage hormone. Once released into the bloodstream, T4 must be converted into triiodothyronine (T3), the active form of thyroid hormone that binds to receptors inside cells and drives metabolic activity. This conversion takes place in several tissues, including the liver, gut, and kidneys.

 

The production and release of thyroid hormones are regulated by a feedback loop involving the brain and pituitary gland. The hypothalamus releases thyrotropin-releasing hormone (TRH), which signals the pituitary to release thyroid-stimulating hormone (TSH). 

 

TSH then directs the thyroid gland to produce and secrete T4 and T3. When thyroid hormones are sufficient, they signal back to the brain to reduce TSH production, maintaining balance. Disruption in any part of this system with production, conversion, or regulation can result in thyroid dysfunction and the need for medication support.

 

Key Thyroid Hormone Markers to Understand

 

 

The following are common thyroid blood work markers:

 

• TSH (Thyroid-Stimulating Hormone): A hormone released by the pituitary gland that signals the thyroid to produce more thyroid hormones. High TSH often indicates underactive thyroid function, while low TSH may reflect overactivity.
• T4 (Thyroxine): The main hormone produced by the thyroid gland. It is largely inactive and must be converted into T3 for the body to use. Standard lab tests usually measure total T4 and free T4.
• T3 (Triiodothyronine): The active thyroid hormone that directly affects metabolism and cellular activity. Measured as total T3 or free T3, this marker gives insight into how well T4 is being converted and utilized by the body.
• Reverse T3 (rT3): An inactive form of T3 created when the body converts T4 into a “blocked” version instead of usable T3. High levels can indicate stress, inflammation, or nutrient deficiencies interfering with healthy conversion.
• Free Hormones (Free T4, Free T3): These reflect the unbound hormones available for immediate use by tissues. They provide a more accurate picture of thyroid status than total hormone levels alone.
• Thyroid Antibodies (TPOAb, TgAb, TRAb): Immune system proteins that attack thyroid tissue, typically present in autoimmune thyroid disorders like Hashimoto’s thyroiditis or Graves’ disease. While not hormones themselves, antibodies help determine whether dysfunction is autoimmune-driven.

 

You can read more in-depth about the thyroid and thyroid hormone here. 

 

What Are Thyroid Medications?

 

 

Thyroid medications are prescription therapies designed to correct imbalances in thyroid hormone levels. 

 

When thyroid function is disrupted, either through underproduction (hypothyroidism), overproduction (hyperthyroidism), or impaired hormone conversion, the result can be a wide range of symptoms that significantly affect quality of life.

 

In conventional care, thyroid medications are typically prescribed for hypothyroidism and Hashimoto’s thyroiditis, the most common autoimmune thyroid disorder. However, thyroid dysfunction usually isn’t an isolated condition. It can also appear as a downstream effect of broader chronic illnesses, even as an autoimmune disorder. 

 

For example, individuals with Chronic Inflammatory Response Syndrome (CIRS), Lyme disease, mold exposure, or systemic autoimmune conditions commonly develop secondary thyroid imbalances. In these cases, thyroid medications may be used as a supportive tool to stabilize hormone levels while practitioners work to address deeper underlying issues.

 

Thyroid Medications In Standard Care vs. Root-Cause Healing

 

 

For standard medical practice, thyroid medications are generally viewed as a long-term, sometimes lifelong, necessity. The focus is on symptom suppression and lab normalization, ensuring TSH and thyroid hormone levels fall within conventional reference ranges. While this can provide important relief, it typically does not explore why the thyroid became dysfunctional in the first place.

 

In contrast, a functional and root-cause approach views thyroid medications as a potential bridge rather than a permanent solution for everyone. 

 

Medications can stabilize patients during times of severe imbalance, but the long-term goal is to investigate and address upstream drivers such as chronic inflammation, nutrient deficiencies, gut dysbiosis, toxin exposures, and immune dysregulation. 

 

This perspective prioritizes the possibility of reducing reliance on medication over time if deeper healing is achieved, while still recognizing that some individuals may benefit from ongoing support.

 

Understanding Thyroid Medication Terminology

 

 

Let’s clarify the terminology around thyroid medications so we are all on the same page. Many of these terms are used interchangeably in clinical and patient discussions, but each has a specific meaning.

 

Natural Desiccated Thyroid (NDT) is a class of thyroid medications made from dried porcine (pig) thyroid glands. Clinically, it contains a blend of thyroid hormones, mainly T4 and T3, plus smaller amounts of T2, T1, and calcitonin. Think of natural desiccated thyroid (NDT) as a “whole food” version of thyroid medication, as it’s meant to provide a full spectrum of hormones similar to what your own thyroid would naturally produce.

 

Desiccated Thyroid Extract (DTE) is simply the formal medical term for natural desiccated thyroid (NDT), used by the FDA and in pharmacology literature. In practical terms, natural desiccated thyroid (NDT) and desiccated thyroid extract (DTE) are the same thing. 

 

Desiccated Thyroid Analogue refers to branded versions of natural desiccated thyroid (NDT) that are manufactured and standardized for consistency, such as Armour Thyroid, NP Thyroid, or Nature-Throid. Like other medications, the active ingredient is the same, but the formulation and processing methods will vary based on brand. 

 

Armour Thyroid is one of the most widely recognized branded versions of natural desiccated thyroid (NDT). Although it comes from porcine thyroid tissue, it is standardized in the lab under United States Pharmacopeia (USP) guidelines to ensure precise hormone ratios and potency. 

 

Levothyroxine is a synthetic, lab-made medication that provides only T4, the storage form of thyroid hormone. Clinically, it’s the most common first-line prescription for hypothyroidism. Because T4 is inactive, the body must convert it into T3 to use it.

 

Liothyronine is a synthetic version of T3, the active form of thyroid hormone that cells can immediately use. Clinically, it’s generally prescribed when patients can’t properly convert T4 to T3. 

 

T4/T3 Combination Therapies can be achieved either naturally through natural desiccated thyroids (NDTs) or synthetically via compounded prescriptions that blend T4 and T3 in specific ratios. 

 

Compounded Thyroid Medications are custom-made by compounding pharmacies. Clinically, they can be tailored to unique patient needs by adjusting hormone ratios, doses, or delivery methods such as slow-release capsules or liquids. 

 

Porcine-Derived vs. Synthetic is the main difference between natural and lab-made thyroid medications. Natural desiccated thyroid (NDT), desiccated thyroid extract (DTE), and Armour Thyroid are considered natural because they come from animal thyroid tissue, while levothyroxine, liothyronine, and compounded synthetics are produced entirely in labs. One is like sourcing nutrients from a whole food, while the other is like taking a vitamin supplement—both are designed to nourish you, but they differ in source, composition, as well as pros and cons.

 

Recent Thyroid Medication Concerns

The following are issues that have been raised by our patients and clients around thyroid medications recently:

 

Issue #1: Thyroid Medications Sourced From Asia Are No Longer Accessible Due to Tariffs

 

 

One of the first concerns we’ve heard is that thyroid medications previously sourced from Asia are no longer available because of tariffs. On the surface, this explanation might make sense, especially with the many headlines over the past several years about trade disputes and pharmaceutical supply chains. 

 

With the Trump administration, foreign drug tariffs have been a frequent topic of debate, and some media outlets are producing fear-driven stories about how these measures could limit access to essential medications.

 

To add complexity, China plays a central role in the global pharmaceutical market. It is widely acknowledged that China controls much of America’s generic drug supply chain, including raw ingredients and finished products for medications such as thyroid prescriptions. Some Americans also purchase thyroid medications in Thailand as certain hormone replacement drugs are available over-the-counter at many local pharmacies there. 

 

This has created longstanding concerns about reliance on foreign countries for essential medicines. In theory, tariffs could raise costs for importers and distributors, making it harder or more expensive for patients to source medications directly from Asia.

 

However, when we step back and look at the situation, the tariff explanation alone doesn’t hold up well. From a business standpoint, pharmaceutical companies are unlikely to stop selling altogether. 

 

Instead, they typically raise prices to offset tariffs because, ultimately, companies want to maintain profits and stay in business. If access has suddenly been cut off, it suggests that another factor is at play. As we’ll explore in the next section, there are additional regulatory forces that seem more likely to explain why individuals may no longer have access to these medications.

 

Finally, it’s worth asking an important question: why place trust in medications sourced from another country without clear oversight? While the US system is far from perfect, there is at least some measure of regulation and accountability when medications are dispensed domestically. Sourcing unregulated medications abroad carries inherent risks, and it’s not surprising that the FDA has taken steps to respond, which ties directly into Issue #2 that we’ll outline next.

 

Issue #2: The FDA Recently Issued Letters to Manufacturers, Importers, and Distributors of Animal-Derived Thyroid Medications (DTE)

 

 

On August 6, 2025, the FDA sent formal letters to manufacturers, importers, and distributors of animal‑derived thyroid medications, commonly known as desiccated thyroid extract (DTE), including brands such as Armour Thyroid and NP Thyroid. 

 

These letters announced the agency’s intent to take enforcement action against these unapproved products unless they achieve compliance with regulatory standards.

 

 

The FDA’s concerns are focused on three specific risks:

 

• Non‑validated safety: Unlike synthetic thyroid medications, desiccated thyroid extract (DTE) products have not undergone rigorous modern clinical trials to establish their safety and effectiveness.
• Inconsistent dosing: Since these medications are derived from animal thyroid glands, potency can vary significantly between batches, making reliable dosing difficult.
• Impurity risks: The animal-derived nature of these products introduces the potential for contamination by biological impurities, including pathogens or improperly characterized compounds.

 

Historically, desiccated thyroid extract (DTE) products have existed in a regulatory gray area. They were introduced long before modern FDA oversight was in place, which meant they were never formally approved under current regulations. 

 

Instead, they were effectively grandfathered in, slipping through because of their early entry into the market rather than being evaluated under today’s standards. The FDA has long maintained that desiccated thyroid extract (DTE) is not officially grandfathered, despite being used for decades as the frontline treatment for hypothyroidism.

 

Concerns around desiccated thyroid extract (DTE) have only grown in recent years. Since late 2017, the FDA has flagged multiple manufacturing violations in desiccated thyroid extract (DTE)-producing facilities. These violations included poor quality control, inadequate stability data, failure to investigate out-of-specification results properly, and inconsistent potency from one batch to the next. 

 

Alongside these concerns, the FDA has tracked more than 500 adverse event reports associated with desiccated thyroid extract (DTE) since 1968, with a sharp spike between 2019 and 2020 when several voluntary recalls were issued for subpotent or superpotent batches. 

 

A particularly notable case occurred in 2020, when Acella Pharmaceuticals recalled certain NP Thyroid lots for underdosing and later acknowledged other lots that were overdosed, leaving many patients suddenly unstable.

 

On August 6 to 7, 2025, the FDA escalated its oversight by sending formal letters to manufacturers, importers, and distributors of desiccated thyroid extract (DTE), warning that unapproved animal-derived thyroid medications would soon be subject to enforcement action. 

 

The letters stated that a transition period of up to 12 months would be allowed to move patients onto FDA-approved thyroid replacements. This shift reflects the FDA’s decision to classify desiccated thyroid extract (DTE) as a biologic drug, meaning that companies must now submit a costly and time-intensive Biologics License Application (BLA) to remain on the market.

 

The FDA’s stance has raised concerns and confusion. In a follow-up communication to the Graves’ Disease and Thyroid Foundation (GDATF) on August 19, 2025, the FDA clarified that it is “committed to advancing the science to support making more treatments available” and noted the importance of desiccated thyroid extract (DTE) for many patients. 

 

FDA Commissioner Dr. Marty Makary also posted on August 13 that the agency is “committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials,” adding that in the meantime, “we will ensure access for all Americans.” While this reassurance is welcome, it contrasts with the 12-month transition language in the enforcement letters and raises questions about whether patients will face forced discontinuation before a BLA is realistically achievable.

 

Industry and advocacy voices have also shaped the debate. AbbVie, the manufacturer of both Synthroid and Armour Thyroid, previously filed a Citizen’s Petition in 2024 and is well-positioned financially to pursue biologic approval. 

 

If Armour Thyroid is the first, and possibly only, natural desiccated thyroid (NDT) product to gain approval, it could dominate the market and potentially drive prices into the biologics category, where treatments typically cost thousands of dollars per month. Patients fear this would make natural desiccated thyroid (NDT) inaccessible even if it becomes FDA-approved.

 

This controversy isn’t new. 

 

Back in 2013, FDA representatives at the American Thyroid Association’s Spring Symposium questioned whether desiccated thyroid extract (DTE) could truly be considered grandfathered, foreshadowing the regulatory battles we see today. 

 

In 2020, the FDA sent letters to both RLC Labs and Acella Pharmaceuticals after site inspections uncovered significant quality concerns.

 

In 2022, the FDA began openly classifying desiccated thyroid extract (DTE) as a biologic product, signaling that compounding pharmacies would no longer be allowed to prepare custom desiccated thyroid extract (DTE) formulas. By late 2022, FDA communications softened slightly, acknowledging patient demand and promising to focus enforcement on cases posing the greatest public health risks, such as serious adverse events or adulteration. (Hence, why compounded formulas are still available today.)

 

Even so, the agency has consistently encouraged physicians to transition patients to FDA-approved therapies like levothyroxine or synthetic T3/T4 combinations. The most recent announcement reiterated that providers should contact patients on desiccated thyroid extract (DTE) and move them to approved options. For many patients, however, this represents a backward step. 

 

A 2017 American Thyroid Association survey of over 12,000 patients found that those taking desiccated thyroid extract (DTE) reported fewer problems with weight, fatigue, mood, and memory compared to patients on levothyroxine alone or levothyroxine with Cytomel. Many had already tried other options unsuccessfully before landing on desiccated thyroid extract (DTE) as the only therapy that provided relief.

 

The scientific debate continues. 

 

Critics point out that desiccated thyroid extract (DTE)’s T4:T3 ratio differs from that of the human thyroid and that higher T3 content may drive hyperthyroid symptoms in some patients. Supporters highlight patient satisfaction, the possibility of genetic differences influencing response to therapy, and the importance of respecting patient choice. Ongoing research, including clinical trials sponsored by AbbVie, is investigating these questions directly by comparing Armour Thyroid to synthetic T4.

 

The Impact On Patient Prescriptions

 

 

It’s understandable to feel worried when headlines suggest that desiccated thyroid extract (DTE) medications may be disappearing. But the reality is, there are strong reasons why patient prescriptions are unlikely to vanish anytime soon.

 

First, this is not a law or a permanent ban. What the FDA has initiated is an enforcement action, essentially a regulatory move to reclassify desiccated thyroid extract (DTE)  as a biologic. As mentioned above, this means manufacturers will eventually need to file a biologics license application, which takes time and money. While that creates uncertainty, the FDA has already stated that patients will not lose access during this process, and ongoing clinical trials are expected to provide the data needed for eventual approval.

 

There’s also a significant financial incentive to keep desiccated thyroid extract (DTE) available. Thyroid medications represent a massive market—levothyroxine alone is consistently one of the top three or four most-prescribed drugs in the US, with 80 to 100 million prescriptions filled each year. 

 

Even though only about 20% of thyroid patients take desiccated thyroid extract (DTE), that still represents tens of millions of prescriptions annually. This is a market worth billions, and manufacturers have every reason to fight for continued access.

 

If the 12-month transition timeline is enforced, this could mean widespread disruption by mid-2026. However, if the agency softens its stance, as it has in the past, patients may see continued access until formal approvals are in place. 

 

While change is likely coming, your prescription is not in immediate danger. The financial stakes, community advocacy, and the FDA’s own statements all point to continued availability of desiccated thyroid extract (DTE) while the regulatory process plays out.

 

Our Perspective

 

 

It’s deeply frustrating to see porcine-derived thyroid medications, which many patients rely on, being removed or restricted, especially when they help individuals feel better than synthetic alternatives. Still, the FDA’s concerns aren’t arbitrary. The issues of inconsistent dosing, lack of safety data, and impurity risks are well-documented and cause real harm.

 

That said, we firmly believe in patient choice, as long as individuals are fully informed about the pros and cons. Ideally, desiccated thyroid extract (DTE) could one day be FDA-approved and reliably regulated. Bolstered by the FDA’s stated commitment, that future is possible but not immediate.

 

Looking back to Issue #1, if pharmacies or providers are suddenly halting access now, it’s likely because they’ve been operating in a regulatory gray zone and now face legal and reputational risks. Their silent withdrawal likely explains that the root issue isn’t tariffs, but evolving FDA enforcement.

 

Issue #3: The FDA Recalled 160,000 Bottles of Levothyroxine Sodium

 

 

On July 24, 2025, the FDA announced the recall of more than 160,000 bottles of levothyroxine sodium, the most widely prescribed synthetic T4 medication for hypothyroidism. Levothyroxine is typically considered the gold standard in conventional thyroid treatment, but this event shows that even synthetic medications are not immune to quality control issues.

 

The recall was issued because certain batches of levothyroxine were found to deviate from their approved potency specifications. Thyroid medications are highly dose-sensitive, and even slight variations in hormone concentration can have significant effects on metabolism, cardiovascular health, and overall well-being. 

 

This recall exemplifies that no thyroid medication is perfect, whether synthetic or natural. 

 

Yes, it is concerning that synthetic thyroid drugs were recalled so recently, but it is also a positive sign that these bottles were pulled from circulation before more patients were harmed. Imagine if this same issue occurred with Armour Thyroid or another desiccated thyroid extract: would it even be recalled? For context, Acella Pharmaceuticals only recalled NP Thyroid in 2021 after subpotent lots had already been distributed, leaving many patients unknowingly under-medicated.

 

At least in this case, the recall demonstrates that some degree of oversight and accountability is working. 

 

Issue #4: Medication Is Removed From the Market and No Longer Available

 

 

A sobering reality in the pharmaceutical landscape is that medications can be pulled from the market entirely, sometimes leaving patients with no access to treatments they relied on. 

 

A well-known example of this is Makena, a drug once used to prevent preterm birth. Originally, Makena existed as a cheap compounded medication that many women could afford. However, when KV Pharmaceutical obtained FDA approval for the branded version of Makena, the company was granted exclusive rights. 

 

The FDA then banned compounded versions, effectively removing all of the lower-cost generics from circulation. The move was heavily criticized as an example of how regulation can protect corporate monopolies rather than patient access.

 

The story didn’t end there. 

 

In 2023, after years of controversy, the FDA withdrew approval for Makena itself due to a lack of efficacy data. In other words, not only did women lose access to affordable compounded versions, but eventually the branded version was also pulled, leaving no FDA-approved treatment available at all for women at risk of preterm birth. 

 

Yes, most people don’t need Makena frequently, but there are cases like these where the generic version is pulled so pharmaceutical companies can make more money on slightly different “new” patented products or control distribution access to make more money (hello, Rockefeller’s Standard Oil). 

 

This isn’t an isolated problem either. 

 

Daraprim, a drug used to treat toxoplasmosis (a parasitic infection especially dangerous for people with compromised immune systems), was once inexpensive and widely available. But in 2015, Turing Pharmaceuticals, led by Martin Shkreli, acquired the rights to Daraprim and overnight increased the price from $13.50 per pill to $750 per pill, a more than 5,000% hike. 

 

No changes were made to the drug itself. The justification was purely financial, exploiting FDA rules that prevented compounded or generic alternatives from entering the market. This shocking example became a cultural flashpoint, showing how access to essential medications can be manipulated for profit, leaving vulnerable patients caught in the middle.

 

Another example is Colcrys, a medication used for gout and pericarditis. Colchicine, the active ingredient in Colcrys, had been available as a cheap generic for decades. But in 2009, after a new clinical study demonstrated safety and efficacy, the FDA granted exclusive marketing rights to Colcrys under the Unapproved Drugs Initiative. 

 

This effectively banned other generic versions from the market. The result was predictable: the price of colchicine skyrocketed from pennies per pill to over $5 per pill, creating financial hardship for patients who suddenly had no affordable alternatives. Again, a drug that had been used safely for decades was now only available in an expensive branded form, all in the name of regulatory compliance and exclusivity.

 

These stories go to show that sometimes patients are left without options because medications are withdrawn, monopolized, or priced out of reach. We see this in our practice at times, patients stuck on medications they can’t afford or can’t easily replace, particularly when financial constraints and life circumstances limit their ability to explore alternatives.

 

And yet, this highlights why root-cause healing must remain the focus. 

 

Being dependent on any medication, even when it provides temporary relief, is not the same as resolving the underlying dysfunction. Thyroid hormones are a perfect example. 

 

Yes, medications can help manage symptoms, and yes, they are sometimes necessary to stabilize patients, but finding the “perfect dose” of thyroid medication is not a true solution. Unless the medication is truly life-saving, the ultimate goal should be reducing or eliminating dependency through diet, lifestyle, and deeper healing.

 

We’ve seen similar cautionary tales in other areas of medicine, like insulin pricing. Even though Type 1 diabetics require insulin to survive, skyrocketing costs have left patients rationing doses, sometimes with devastating consequences. While insulin is essential in these cases, even here we see that diet and lifestyle can significantly reduce medication needs. 

 

The same applies to thyroid health. Sure, find out if you are imbalanced in any thyroid markers and take some medications if it will give you energy or manage other symptoms, but please know that it’s not a root-cause answer. After working with thousands of patients, our experience strongly suggests that most cases of thyroid imbalances are not caused by genetics alone, but rather by systemic imbalances and inflammation that can be addressed at the root level. 

 

So, while it is natural to fear which thyroid medication may come off the market next, the real solution lies elsewhere. Instead of worrying about whether Armour Thyroid, NP Thyroid, or levothyroxine will remain available, the focus should be on why your thyroid is imbalanced in the first place. 

 

Medications can support you in the short term, but long-term empowerment comes from true sovereignty over your wellness and choices. That means addressing diet, lifestyle, environmental triggers, and root causes so that, eventually, medication dependency is minimized or eliminated.

 

Only a very select few, usually those battling chronic illness for decades, will need thyroid medication long-term. For everyone else, the path forward should be about regaining balance and building resilience from the ground up. That road is more challenging, yes—but it is also the only way to ensure that your health and your future are not at the mercy of the pharmaceutical marketplace.

 

What About Genetic Hypothyroidism?

 

 

Whenever we talk about root-cause healing and thyroid health, a frequently asked question is: What about people who are simply born with hypothyroidism? 

 

This is an important nuance, because while most cases of hypothyroidism are acquired later in life, there is a small subset of cases that are indeed congenital.

 

A comprehensive meta-analysis of over 330 million newborns found that congenital hypothyroidism (CH) occurs at a global prevalence of about 4.25 per 10,000 births. Of these cases, only a fraction, roughly 2–5%, are linked to inherited genetic mutations such as PAX8, TSHR, or TG mutations. 

 

In the US, where about 900 to 1,800 cases of congenital hypothyroidism (CH) are diagnosed annually, this translates to only 18 to 90 cases per year that are genetic in origin. For perspective, TG mutations account for only 9 to 18 cases annually in the US.

 

The overwhelming majority of congenital hypothyroidism (CH) cases are sporadic, meaning they are not inherited but arise from structural or developmental issues in the thyroid gland or hypothalamic-pituitary axis. For example, thyroid dysgenesis, abnormal formation or migration of the thyroid gland in utero, is a leading cause of congenital hypothyroidism (CH) and does not follow a hereditary pattern.

 

To zoom out even further, the numbers tell a clear story: around 12 million people in the US live with hypothyroidism, yet more than 99% of those cases are acquired rather than genetic. Most are due to autoimmune processes or environmental triggers that disrupt thyroid function over time. 

 

This is why, even though family history may play a role, hypothyroidism is rarely a “purely genetic” destiny. Most illnesses, including thyroid disease, are multifactorial, with genetics, environment, lifestyle, and immune function all playing interconnected roles.

 

While the overwhelming majority of cases are acquired, there is indeed a small but real subset of individuals born with congenital or genetically driven thyroid dysfunction. For those individuals, thyroid medication may be necessary long-term, as structural or genetic limitations can’t always be corrected through diet or lifestyle alone.

 

That said, for the vast majority of people living with hypothyroidism, including those who may have a family history of thyroid disease, the condition is acquired and heavily influenced by environmental and lifestyle factors.

 

Additional Considerations Around Thyroid Medications

 

 

To further challenge the notion that thyroid medications should be used long-term, recent studies raise important questions about when treatment is truly necessary and whether medications always deliver the benefits patients expect.

 

For example, a 2022 review paper examined the treatment of subclinical hypothyroidism, a condition defined as elevated TSH (above 4.5) with normal T4 levels. The review concluded that treating patients in this category with levothyroxine did not improve quality of life. 

 

Symptoms such as fatigue, weight gain, or brain fog often persisted, even when lab numbers were normalized. This finding challenges the idea that every mild thyroid imbalance requires immediate pharmaceutical intervention.

 

 

In August 2022, a retrospective cohort study involving 412 participants provided further context. Over a three-year period, researchers tracked outcomes for individuals with subclinical hypothyroidism:

 

• 46.5% normalized thyroid levels on their own, without any intervention.
• 45.8% remained in a subclinical state.
• Only 4.6% progressed to overt hypothyroidism, defined as TSH above 10 with abnormal T4 levels.

 

In other words, nearly half of the participants naturally regained balance, and the overwhelming majority, 95%, never became fully hypothyroid. 

 

Yet, in real-world practice, many of these individuals would have been placed on medication early. The question becomes: how many would have experienced real symptom relief? Research suggests that the answer is not many.

 

Why Medications Don’t Solve the Problem

 

 

Thyroid markers reflect deeper physiological processes, and simply supplementing with hormones doesn’t usually resolve the underlying imbalance:

 

• Low T3 isn’t automatically fixed by giving more T3. Poor conversion from T4 to T3 can be driven by chronic stress, nutrient deficiencies (selenium, zinc, iron), or inflammation.
• High TSH isn’t always corrected with glandulars or synthetic hormones, especially if the pituitary-thyroid feedback loop is being disrupted by autoimmune activity or environmental triggers.
• Thyroid antibodies don’t disappear just by removing dairy or any single food. Autoimmunity is multifactorial, typically requiring a broad root-cause approach addressing gut health, toxins, and immune regulation.

 

This is why many patients chase lab numbers without ever feeling better long-term. If finding the perfect dosage of thyroid medication were truly the answer, we wouldn’t see so many people cycling through different brands, doses, or combinations in search of relief.

 

Thyroid Medication Risks

 

 

It is also important to note that thyroid medications are not without risks. Beyond inconsistent efficacy for subclinical cases, studies have shown that overtreatment with levothyroxine increases the risk of atrial fibrillation (irregular, rapid heartbeat) and bone loss, particularly in older adults. 

 

Another retrospective multicenter study found that patients with long-term levothyroxine use had a higher incidence of cardiovascular complications, including heart failure and stroke.

 

Real Talk On Thyroid Medication Concerns

If you are on thyroid medication solely because of slightly imbalanced markers, and assuming fatigue or weight gain is truly thyroid-related, it is worth considering all possible dietary and lifestyle interventions before committing to a lifelong prescription. 

 

The body keeps score, and it absolutely has a balance sheet. Stress, nutrient deficiencies, environmental toxins, infections, and poor sleep can all contribute to thyroid dysfunction, and these are commonly overlooked when the reflex is simply to prescribe medication.

 

The recent concerns around thyroid medications, whether it’s FDA enforcement, recalls, tariffs, monopolies, or removals, are important and valid. These developments create real stress and uncertainty for patients who rely on these prescriptions. 

 

However, our experience in clinical practice has shown that it is actually quite rare for someone to truly need thyroid medication long-term once they’ve gone through the process of addressing root-cause healing.

 

Yes, medications can provide a bridge. 

 

They can stabilize symptoms and give patients relief while deeper healing takes place. But when we see patients continue to struggle despite “perfect” lab numbers or carefully adjusted doses, it becomes clear that medication alone is not the solution. 

 

True health freedom comes from uncovering and resolving the why behind thyroid dysfunction. That means addressing root-cause drivers in a structured, personalized way.

 

When patients commit to completing root-cause healing protocols, the outcome is powerful. They gain resiliency. They begin to live nearly symptom-free lives. And, most importantly, they are no longer dependent on a fragile pharmaceutical supply chain or at the mercy of regulatory decisions made behind closed doors.

 

Our goal has always been to empower patients to get off as many medications and supplements as possible—not because we oppose their use, but because freedom means not needing them to function day to day. Thyroid medications can and do have their place, especially as a short-term support. Still, the ultimate goal should always be a thriving, balanced body that no longer requires constant external management.

 

So while these recent concerns around thyroid medications are valid and worth understanding, they also illuminate why we continue to advocate for root-cause healing above all else. That is the path to true sovereignty over your health, and the surest way to ensure your wellness is never dictated by the shifting tides of the pharmaceutical marketplace or government regulatory systems.

 

Work With Our Trusted Carnivore Diet Functional Medicine Practitioners

Our Empower Functional Health practice is honored to be trusted carnivore diet functional medicine practitioners, supporting patients and clients from around the globe. We’re passionate about helping individuals achieve root-cause healing in order to live the life they are meant to, nearly symptom-free. We provide holistic health thought leadership and evidence-based insights, paired with clinical pearls, to help you achieve your wellness goals. We welcome you to explore our free resources, and if you find that self-troubleshooting falls short, we’re here to guide you with personalized support and protocols. Our Personalized Health Plan (PHP) is the ideal starting point for uncovering your root causes. You can learn more about this powerful, proprietary tool in-depth here.

 

 

DISCLAIMER: This content is for educational purposes only. While we are board-certified in holistic nutrition and are functional practitioners, we are not providing medical advice. Whenever you start a new diet or protocol, always consult with your trusted practitioner first.